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Available online 3 August 2016Background: Recombinant human bone morphogenetic protein 7 (rhBMP7) is applied for treatment of bone
fractures, especially tibial non-unions. Its application may induce autoantibodies (aAB) affecting the targeted
and endogenous signaling pathways and in turn negatively impact treatment efﬁcacy.
Methods: Novel and sensitive assays for the quantiﬁcation of BMP7-aAB and BMP2-aAB were established and
used to analyze serum samples from healthy controls (n = 100 men, n = 100 women) and patients with long
bone fracture (n= 265) treated or not with rhBMP7. Sera from three to nine time points per patient were avail-
able and enabled the evaluation of aAB over a time course of up to one year. Functional activity of the BMP-aAB
was tested with a BMP-responsive cell-based reporter assay. Consolidation of the fracture was evaluated as
clinical outcome potentially affected by BMP7-aAB.
Results: Prevalence of BMP7-aAB and BMP2-aAB was 1–2.5% in non-treated patients or healthy controls. The
rhBMP7 treatment induced a transient increase in BMP7-aAB in a subset of patients, returning to non-
detectable levels within six months. IgG from BMP7-aAB positive sera inhibited dose dependently the BMP7-
reporter gene activity, whereas control sera were without effect. Successful consolidation of the fracture was
observed in the majority of both aAB-positive and aAB-negative patients.
General signiﬁcance:Weconclude that BMP7-aAB canbe detected as natural aAB inhealthy subjects, and are tran-
siently induced by rhBMP7 therapy in a subset of patients. The aAB are capable of antagonizing BMP7 signaling
in vitro, but do not preclude treatment success in patients.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Bone is a tissue with a remarkable regenerative potential controlled
in part by bone itself and by the interplaywith the immune and vascular
systems [1]. After fracture, bone often regenerates completely to its
original composition without the formation of a scar. It can therefore
be considered as a truly regenerative tissue. Usually, a fracture gap is
closed within 3–6 months after trauma. However, some fractures
(approx. 10%) show healing difﬁculties leading to delayed healing, or
non-unions also known as pseudarthrosis. There are a number of
parameters affecting the healing process including the severity of the
initial insult as well as age and health of the patient [2–4].elle Endokrinologie, Charité -
lin, Germany.
burg).
. This is an open access article underA compromised healing situation requires an intervention to reacti-
vate and enhance natural bone formation. The major aspects that
need to be considered are osteogenic cells, osteoconductive scaffolds,
osteoinductive stimulants (hormones and local growth factors) and
the mechanical environment, summarized as the diamond concept [5]
which was extended by the aspect of vascularity [6]. Interventions
according to the diamond concept involve an assessment of all of
these aspects for a given patient and the attempt to optimize the thera-
peutic measures resulting in an individualized therapy plan. Treatment
of non-unions following this concept proved to be a reasonable and
successful strategy [7–9]. In early stage the therapeutic treatments in
delayed union may include biophysical stimulation, e.g. full weight
bearing, low-intensity pulsed ultrasound, shockwave or electromagnet-
ic ﬁeld stimulation. Biological enhancement of bone regeneration is the
base in treatment of non-unions. Autologous cancellous bone graft is
considered the gold standard in the surgical treatment of non-unions,
but the limited availability is problematic [15]. Amongst the locallythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Study design. Fracture patients were divided into two groups (treated or not with BMP7)
that received differential surgical treatments.
BMP7 treatment Patients
[n]
Treatment groups Patients
[n]
BMP7-aAB over
time, patients
[n]
Fracture treatment
w/o BMP7
178 Fresh fractures 145 5
Pseudarthrosis 33 1
Fracture treatment
with BMP7
87 Pseudarthrosis 38 2
Pseudarthrosis
RIAa or Spongiosa
21 2
Pseudarthrosis
Masqueletb
28 3
a RIA, reamer irrigator aspirator.
b Masquelet, use of temporary cement spacer.
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as osteoconductivematerial, growth factors like erythropoietin,ﬁbroblast
growth factors or bonemorphogenetic proteins (BMPs) as osteoinductive
agents and synthetic polymers or autologous bone as osteogenicmaterial
[10].
BMPs belong to the transforming growth factor beta (TGFβ) super-
family and are pleiotropic paracrine growth factors that are involved
in the regulation of diverse biological processes such as proliferation,
survival, apoptosis, differentiation andmigration of cells [11]. Thediffer-
entmembers of the TFGβ-superfamily perform speciﬁc tasks during de-
velopment and homeostasis in various tissues [12]. The groundwork of
BMP research in bone was laid in the late 1960s by Marshal Urist when
he showed that implanted demineralized bone induced ectopic bone
formation in skeletal muscle [13]. Later, the nature of these bone
forming factors were identiﬁed and termed BMP [14]. The correspond-
ing DNA was cloned and recombinant protein was expressed shortly
after [15].
These achievements paved the way for applying recombinant
human BMP (rhBMP) to improve bone regeneration and fracture
healing. To this end, especially rhBMP2 and rhBMP7 have been tested
and further developed to therapeutic biologicals as osteoinductive
growth factors andworkmost efﬁcient in combinationwith autologous
bone material [16–19]. BMP2 and BMP7 induce osteoblast and
chondrocyte differentiation thereby increasing intramembranous and
endochondral ossiﬁcation. Both BMPs have been approved for use in
humans by the FDA in 2001 and 2004, respectively, and have shown re-
markable therapeutic effects in the last decade. However, concerns re-
garding their safety and side-effects were raised, especially with
respect to ectopic bone formation, osteolysis, induction of autoimmuni-
ty, cancer, or problems related to cost effectiveness, collectively limiting
their use in recent years [20].
The potential induction of autoantibodies (aAB) against rhBMP
(BMP-aAB) may be of clinical relevance for three major reasons. First,
BMP-aAB might interfere with the biological activity of the therapeutic
rhBMP by neutralizing it. Second, rhBMP-aAB complexes may cause un-
wanted immune reactions. And third, treatment-induced BMP-aAB
might cross-react with endogenous BMP thereby interfering with the
regular signaling pathways.
In order to test for natural occurring and treatment-induced BMP-
aAB, we developed two novel luminometric assays. We determined
the prevalence of BMP7-aAB and BMP2-aAB in healthy subjects and in
patients with severe fractures treated or not with rhBMP7, and at time
points before and after surgery. Our data indicate that rhBMP7 treat-
ment transiently induces BMP7-aAB in a subset of patients, and that
these aAB are antagonists for BMP7 signaling in vitro. However, fracture
consolidationwas successfully achieved in both BMP7-aAB-positive and
BMP7-aAB-negative patients, indicating that these aAB do not preclude
treatment success.
2. Material and methods
2.1. Patients
Serum samples from a cohort of 200 anonymized healthy donors
(100 males and 100 females, age range; 21 to 40 years) were obtained
from a commercial supplier (Invent GmbH, Biotechnology Center
Hennigsdorf, Germany). Serum samples from fracture patients
were collected at the Department of Orthopedics and Trauma Sur-
gery, Heidelberg University Hospital. Two time points were analyzed
from 265 patients with long bone fracture (189 females, 76 males),
yielding a total collection of 530 samples. The ﬁrst time point was
around surgical intervention (either pre-surgery or two days after
surgery), and the second time point was approximately four weeks
after surgery. The patients were categorized into different groups
according to whether they have been treated with rhBMP7 or not
(Table 1).The study was conducted in accordance with the declaration of
Helsinki. All individuals providedwritten consent to the study protocol.
The studywas approvedby the ethics committee of theRuprecht- Karls-
University of Heidelberg (S-636/2011).
2.2. Quantiﬁcation of BMP7-aAB and BMP2-aAB
The rhBMP7 used in the osteoinductive therapeutic intervention
was used as bait to establish a novel assay for detection and quantiﬁca-
tion of naturally occurring and therapy-induced aAB against BMP7. For
reasons of testing the speciﬁcity, a second analogous assay for aAB
against BMP2 was established. To this end, 0.1 mg of collagen-free
rhBMP7 (Olympus Biotech) or rhBMP2 (Metronic) were labelled with
acridiniumester-N-hydroxy-succinimid (MACN, InVent Diagnostica
GmbH) in an amine-free buffer. The labelling reactions were stopped
by adding 1 M Tris, pH 7.5. The MACN-labelled rhBMP7 or rhBMP2
was diluted in buffer (PBS, 1% BSA, 0.1% NaN3) and separated from un-
bound MACN using 10 kDa MWCO centrifugal ﬁlter units (Centricon
Ultracel-10K, Millipore, Eschborn, Germany).
After optimizing the conditions of BMP7- or BMP2-aAB detection
and quantiﬁcation, the following protocol was established and used
throughout this study. Serum samples (10 μl per reaction) were
incubated with diluted MACN-labelled rhBMP2 or rhBMP7 (100 μl per
reaction) and incubated at 4 °C overnight. The next day, IgG were
bound by incubation for 1 h shaking at 300 rpm at room temperature
with a solution of a 10% protein A slurry in PBS (PorosA®, 50 μl, Applied
Biosystems). The samples were washed three times with 1 ml washing
buffer (50 mM KH2PO4/K2HPO4 pH 7.5, 100 mM NaCl, 0.1% TritonX-
100), the pellet was precipitated by centrifugation (5 min, 3500 rpm,
20 °C) and the supernatant was aspirated. The chemiluminescence of
the bound MACN-labelled rhBMP2 or rhBMP7 was measured in a
chain luminometer (Autolumat Plus LB 953, Berthold Technologies,
Bad Wildbad, Germany). For the characterization of the assay and as
positive controls, anti-BMP7 and anti-BMP2 antibodies were used.
Mice were immunized with rhBMP7 and monoclonal anti-BMP7 anti-
bodies were generated by a commercial partner (UNICUS Karlsburg
OHG, Greifswald, Germany). A commercial anti-BMP2 antibody
(CYT-26591) was purchased (Dianova, Hamburg, Germany). Both anti-
bodies were applied in a concentration of 100 μg/ml in the control
experiments.
2.3. Isolation of IgG
Total IgG of BMP7-aAB positive and negative sera were isolated by
precipitation with protein A. Serum samples (300 μl) were incubated
with a slurry of 50% PorosA® in PBS (600 μl) and incubated overnight
at 4 °C under constant agitation. The supernatants were discarded and
the pellets were washed six times with PBS. Precipitated IgGwere elut-
ed with 25 mM citric acid, pH 2.2. Seven fractions (500 μl each) were
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of the eluate was reduced by spinning in centrifugal ﬁltration units
(Centricon YM-50, Amicon, Millipore), adjusted to a volume of 300 μl
and stored at 4 °C until use.
2.4. BMP-reporter assays
To test for potential effects of BMP-aAB on BMP signaling in vitro, we
used a BMP-responsive-element (BRE)-containing reporter plasmid,
kindly provided by Prof. Dr. Peter ten Dijke [21]. NIH3T3 cells (ATCC®
CRL-1658™) were cultured in standard medium (DMEM/F12, 10%
FBS). Cells were seeded on 96 well assay plates (white, clear bottom,
Corning Incorporated, NY, USA) at 10,000 cells per well. The next day,
cells were transfectedwith the BRE reporter and a control plasmid of se-
creted alkaline phosphatase (SEAP) under the control of SV40 promoter
(pSEAP2, secreted alkaline phosphatase, Clontech) by use of 40-kDa lin-
ear polyethylenimine reagent (PEI-40, Sigma, Munich, Germany). On
the third day, the cell culturemediumwas exchanged formediumwith-
out FBS, the IgG preparations of BMP7-aAB positive or negative patients
were added, and the cells were stimulated with rhBMP7 or rhBMP2
(0.5 nM, f.c.). The experiments were performed in sextuplicates for
BMP7 stimulation and in triplicates for BMP2 stimulation. After 24 h of
stimulation, the supernatants were collected and SEAP activity was de-
termined using the SEAP substrate Tropix CSPD (Applied Biosystems)
pre-diluted 1:5 in substrate buffer (100 mM Tris, pH 9.5, 100 mM
NaCl, 5 mMMg2+). After 20 min of incubation, SEAP activity (relative
light units, RLU) was measured for 2 s per well in a plate luminometer
(Mithras LB940, Berthold). BRE reporter activity was determined after
cell lysis from the homogenates by injection of 30 μl ﬁreﬂy luciferase
substrate (25 mM glycyl-glycine, 7.5 mMMgSO4, 2 mM EGTA, 7.5 mM
KPO4, pH 7.8, 5 mM DTT, 1 mM ATP, 0.1 mM luciferin). Relative light
units (RLU) were measured for 2 s, normalized to the according SEAP
activity and compared to the unstimulated control.
2.5. Statistical analysis
The data were analyzed by SPSS 19.0 (SPSS Inc., Chicago, IL, USA) or
GraphPad Prism version 5.01 for Windows (GraphPad Co., La Jolla, CA,
USA). Samples were classiﬁed as positively containing BMP-aAB (auto-
antibody positivity) when the measured signals exceeded a ﬂoating
cut point calculated by adding 1.5 times the inter quartile range (IQR)
of the sample cohort to the value deﬁning the 75th percentile
(P75 + 1.5 × IQR). This deﬁnition is relatively robust and applicable to
data sets containing many or no positive samples, as outliers above a
certain background noise are reliably and speciﬁcally detected.
Kolmogorov-Smirnov test for normality of signal distribution was per-
formed and normal distribution was veriﬁed for all conditions tested.
A t-test was performed for calculating the effect of BMP-aAB on the
signaling efﬁcacy of rhBMP7 in vitro.
3. Results
3.1. Assay establishment and characterization
The novel autoimmune assays rely on labelled rhBMP7 or rhBMP2 as
bait for the aAB, and on the isolation of the aAB-rhBMP7 or aAB-rhBMP2
complexes from human serum by protein A-mediated precipitation of
IgG. After washing the protein A pellet containing the labelled BMP
bound by IgG, the chemiluminescence measured directly correlates to
the amount of BMP7-aAB or BMP2-aAB present in the sample. In order
to generate a positive control, mice were immunized with rhBMP7, hy-
bridoma cells were generated by a commercial partner, positive cells
were identiﬁed, expanded, and monoclonal antibodies against rhBMP7
were isolated. One monoclonal antibody was chosen for reasons of
speciﬁcity and used to characterize the BMP7-aAB assay. Signal intensi-
ty correlated to monoclonal antibody concentrations over a dilutionrange from 0.4–25 μg/ml, i.e., over almost two orders of magnitude
(Fig. 1-A). Similarly, when comparing BMP7-aAB positive and negative
sera, signal intensities correlated to aAB concentrations in diluted sam-
ples over more than one order of magnitude (Fig.1-B). Signal intensities
of the three aAB-negative samples were highly reproducible with little
signal variations over the dilution range and yielded comparable RLU
to the PBS background control (Fig.1-B). The BMP2-aAB assay was
veriﬁed with a commercial anti-BMP2 antibody (Fig. 1-C). These results
indicate a successful establishment of novel assays for detecting and
quantifying human BMP2 or BMP7 autoimmunity.
3.2. Prevalence of BMP7- and BMP2-aAB in control subjects
The presence of naturally occurring BMP7- and BMP2-aAB was test-
ed in a cohort of 200 healthymen andwomen. Using the 75th percentile
(P75) plus 1.5-times the interquartile range (IQR) as criterion for posi-
tivity, ﬁve out of 200 samples (2.5%) were classiﬁed as containing
BMP7-aAB (Fig. 2-A), and a similar prevalence for BMP2-aAB was
determined (Fig. 2-B). Four of the BMP7-aAB positive probands were
female and one was male, with an age of 25, 37, 38 (2×), and
39 years, respectively. The BMP7- and BMP2-aAB signals were of mod-
erate strength, and the RLU values exceeded themedian signal intensity
by 2–5 times on average. On the basis of these data, relative units of
BMP7- and BMP2-aAB titers were deduced in relation to the median
(Fig. 2).
3.3. Prevalence of BMP7- and BMP2-aAB in patients with bone fractures
The same assay and criterion for positivity were used in an analysis
of BMP7- or BMP2-aAB in fracture patients. In the collection of 530
serum samples (265 patients measured at two time points), a total of
28 (5%) samples yielded RLU above the cut point of the BMP7-aAB
assay (Fig. 3-A), and 14 samples (2.5%) were positive in the BMP2-aAB
assay (Fig. 3-B). In comparison to the BMP7-aAB signals detected from
thehealthy subjects, the positive signalswere higher for the fracture pa-
tients exceeding the median RLU signal by up to 10 times. This was not
the case for the BMP2-aAB signals. According to the therapeutic inter-
ventions, patients were divided into rhBMP7-treated (n= 87 patients)
or rhBMP7 naïve subjects (n = 178 patients) (Fig. 3-C). In the rhBMP7
naïve group, 2 patients (1% of the subgroup)were foundBMP7-aABpos-
itive at surgery and 3 patients (2%) four weeks after the surgery. In the
rhBMP7 treated group, a higher prevalence was found, i.e., 5 patients
(6%) were measured as BMP7-aAB positive at surgery and 16 patients
(18%) four weeks later. In this latter group the average signal intensity
of the positive samples was also considerably higher compared to the
rhBMP7 naïve group. The majority of patients (n = 244) were tested
negative throughout the study, while 5% of the patients (n = 14)
newly developed BMP7-aAB (Fig. 3-C), whereas no sampleswere highly
positive for BMP2-aAB, independent of BMP7 treatment (Fig. 3-D). The
number of samples with cross-reaction towards both BMP7 and BMP2
was relatively small (n = 4).
3.4. Variations of BMP7-aAB concentrations with time
To study the persistence of BMP7-aAB titers over time, seven posi-
tive and six negative subjects were selected based on signal strengths
and availability of longitudinal serum samples, and between three and
nine additional time points were analyzed (Fig. 4). All of the patients
originally classiﬁed as negative based on their pre- and post-surgical
sample remained negative at all the additional time points analyzed.
The patients that were tested positive for BMP7-aAB in the initial screen
either at the time point before surgery or after surgery or at both time
points showed a varying pattern of BMP7-aAB titers. In general, most
of these patients developed a peak of aAB titers in the ﬁrst days and
weeks after surgery that proved dynamic and transient, returning to
baseline levels within the time range analyzed. One patient showed
Fig. 1. Assay characterization. Linearity and reproducibility of the luminometric signal was tested by (A), using a monoclonal BMP7 antibody; (B), by serial dilutions of positive and
negative serum samples (positive, black; negative, grey); and (C), by a commercial polyclonal antibody against BMP2. Nearly linear signals spanning a wide range of concentrations
were recorded for both the monoclonal antibody and the BMP7-aAB positive sera derived from the cohort of fracture patients (# 11, 12, 14). The signals obtained from the negative
sera (# 7, 10, 9) identiﬁed in the same cohort of fracture patients are constant over the whole dilution range. (C) The BMP2-aAB assay was tested by a serial dilution of a polyclonal
BMP2 antibody yielding a similar detection range as in the BMP7 assay. n = 2; mean ± SD.
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however, only three time points up to 3 months after surgery were
available from this patient, and therefore the potentially transient
nature of the aAB peak could not be veriﬁed in this subject.Fig. 2. BMP7- and BMP2-aABmeasurement in healthy probands. A set of 200 control subjects (n
for BMP7- andBMP2-aAB. Samples are classiﬁed as aAB positivewhen the luminometric signal e
and is set as 1 relativeunit of BMP7- or BMP2-aAB. (A) Five samples (2.5%) exceed the cut point a
considered BMP2-aAB positive.3.5. Clinical treatment success in relation to BMP7 autoantibodies
The group of fracture patients analyzed is very heterogeneous in
terms of fracture type, previous therapeutic interventions, general=100 healthymen and n= 100 healthywomen, age range 21–40 years) were analyzed
xceeds the P75+1.5 IQR cut point (dashed lines). Themedian is indicated by the solid line,
nd are consideredBMP7-aABpositive. (B) Five samples (2.5%) exceed the cut point and are
Fig. 3. BMP7- and BMP2-aABmeasurements in fracture patients. Analysis of 530 samples from 265 fracture patients treated or notwith rhBMP7. (A) Of all themeasured samples, 5% show
signals above the cut point (dashed line) indicating positivity for BMP7-aAB. Some of the BMP7-aAB signals are up to 10 times above the median. (B) The respective number of samples
positive for BMP2-aAB is considerably smaller. (C) The prevalence of BMP7-aAB is higher in the BMP7 treated group with 6% positive patients at surgery and 18% fourweeks after surgery
compared to the untreated group with 1–2% BMP7-aAB positive sera at these time points. Dotted lines connect the samples for a given patient from time point surgery to 4 weeks after
surgery. (D) BMP2-aAB detection divided by treatment groups showed 2% of aAB positive samples in the BMP7-naïve group both before and after surgery. Four weeks after BMP7
treatment, the number increased to 6% BMP2-aAB positive patients, albeit without strongly positive reactions.
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Nevertheless, in order to get a ﬁrst impression on the therapeutic im-
portance of the BMP7-aAB, the parameter consolidation describing
whether the fracture healing process was successful or not in closing
the fracture gap by newly formed bone determined by X-ray, was cho-
sen for analysis. The relative number of BMP7-aAB positive patients is
higher in the group of patients without consolidation as compared to
successfully treated patients (Fig. 5). However, the samples with the
highest relative BMP7-aAB titers are found in the successfully treated
group. These ﬁndings indicate that BMP7-aAB do not preclude success-
ful consolidation in general.
3.6. Biological activity of BMP7-aAB in vitro
In order to test whether the human BMP7-aAB are biologically
active, an in vitro reporter assay was established with a BRE reporter
plasmid and conducted with IgG preparations from the human serum
samples. NIH3T3 cells were transfected with the BRE reporter and
pSEAP2 for normalization, and rhBMP7 or rhBMP2 was applied as
reporter stimulus (Fig. 6-A, -B). PBS served as solvent control and did
not activate the reporter, while rhBMP7 (0.5 nM f.c.) or rhBMP2
(0.5 nM f.c.) induced reporter gene activity N15-fold over control. As
positive control for BMP7-speciﬁc immunoglobulins, the monoclonalBMP7 antibody (BMP7ab) was applied (Fig. 6-A). Co-incubation of
rhBMP7with BMP7ab completely blocked the reporter signal highlight-
ing its antagonistic activity. Next, IgG preparations from three different
BMP7-aAB positive and four BMP7-aAB negative sera from the cohort of
fracture patients were applied. Reporter signal strengthwas completely
repressed to basal levels by all three BMP7-aAB positive samples, similar
as seen for the BMP7ab, whereas the IgG preparations from the BMP7-
aAB negative subjects were without effect. In a second set of experi-
ments, the interaction of BMP7-aAB with BMP2-dependent signaling
was tested. As positive control for BMP2-speciﬁc immunoglobulins, a
polyclonal BMP2 antibody (BMP2ab) was applied (Fig. 6-B). Again, the
co-incubation of rhBMP2with BMP2ab completely blocked the reporter
signal. When the same IgG preparations from the three BMP7-aAB pos-
itive sera mentioned above were tested, no consistent inhibition of
BMP2-stimulated reporter gene activity was recorded. Only one of the
positive samples (IgG 11) suppressed the BMP2-stimulated activity,
while all the other positive or negative IgG preparations were without
effect. Collectively, these results indicate that there is no general cross-
reactivity of BMP7-speciﬁc aAB to the BMP2 pathway, but that cross-
reactivity in certain subjectsmay occur. In this case, the patient showing
positive immunoreactivity against both BMP2 and BMP7 (number 11)
was successfully treated and experienced full consolidation of the
fracture.
Fig. 4. BMP7-aAB trend over time. The patients that were tested positive for BMP7-aAB
showed a transient occurrence of aAB. In most cases BMP7-aAB positivity returned to
undetectable levels within two months. In one patient (Patient # 6) a decline was not
observed in the samples available for analysis (green). The negative control sera from
the same study showed a steady signal at background level (black). BMP7-aAB positive
sera (Patients 1–7); BMP7-aAB negative sera (Patients 8–13). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
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In this study, two novel assays for the detection and quantiﬁcation of
aAB against BMP7 and BMP2 are described. The assays are reproducible,
the signals are linear upon dilution of control antibodies, and the assays
have been validated by speciﬁc antibodies against BMP7 and BMP2, re-
spectively. Using a robust and prudent criterion for positivity, we have
detected BMP7- and BMP2-aAB both in healthy controls and in fracture
patients. The general recommendations on how to develop aAB assays
and test the functionality of aABs have been taken into account during
the course of this study [22–25].Fig. 5. BMP7-aAB concentrations and fracture healing outcome. Fracture patients were
divided into those that had a positive healing outcome (consolidation) and those in whom
the treatment failed (no consolidation). At surgery both groups showed a prevalence of
BMP7-aAB positive samples of 3%. The prevalence of BMP7-aAB positive subjects was
higher 4 weeks after surgery, especially in the group where no consolidation was
diagnosed. However, highest BMP7-aAB titers were detected in samples from successfully
treated patients who developed fracture gap closure and complete consolidation.
Fig. 6. Biological activity of BMP7-aAB. IgG preparations from BMP7-aAB positive and
negative serum samples were analyzed using the BRE-luciferase reporter system. NIH3T3
cells were transfected with BRE reporter construct and pSEAP2 for normalization.
(A) Transfected cells react to stimulation with 0.5 nM rhBMP7 by ﬁreﬂy luciferase
expression. The wells were co-incubated with either a monoclonal BMP7-antibody
(BMP7ab) as positive control, or IgG preparations from BMP7-aAB positive (pos 11, 13,
14) or negative (neg 1, 5, 6, 7) serum samples. Co-incubation with BMP7-aAB positive
IgG preparations blocked the signal in all three cases, as does the monoclonal BMP7ab.
Co-incubation with IgG preparations from BMP7-aAB negative subjects had no effect on
BMP7 signaling. (B) Using the same cell culture BMP reporter system, co-incubation with
BMP2 induced a luciferase signal which was inhibited by co-incubation with a polyclonal
BMP2-antibody (BMP2ab). Co-incubation of BMP2 with IgG from BMP7-aAB positive
samples suppressed the BMP2 signal in one (IgG 11) of three cases. No effect on the
reporter activity was detected for the other two BMP7-aAB positive or the BMP7-aAB
negative preparations. n = 6 (BMP7); n = 3 (BMP2); mean + SD; Student's t-test; ***,
P b 0.0001.The difference in prevalence of BMP7-aAB observed between patients
treated or not with rhBMP7 further supports the notion that this novel
assay is capable of measuring both naturally occurring and rhBMP7-
induced aAB against BMP7. Final proof of the reliability of the novel
assay is given by the functional characterization of IgG preparations
from human serum samples, indicating that only BMP7-aAB positive
preparations were capable of antagonizing BMP7-signaling, but not
BMP7-aABnegative preparations.Moreover,most of the IgGpreparations
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pressing BMP2-stimulated reporter gene activity, verifying the speciﬁcity
of these aAB. These results highlight the quality of the novel BMP7-aAB
assay, and indicate that the BMP7-aAB detected by the novel assay are ca-
pable of reacting with recombinant human BMP7 and interfering with
BMP7 signaling.
The prevalence of 2.5% for BMP7-aAB in healthy adults is in linewith
a previous study that described a prevalence of 1.6% and 3% of naturally
occurring aAB against BMP7 in subjects younger or older than 65 years
of age [26]. Collectively, these data indicate that a small fraction of
healthy adults are already positive for BMP7-aAB despite not having
been exposed to rhBMP7 before in their life. In contrast to our analysis,
the former study reported a prevalence of up to 50% in BMP7-treated
patients [26]. This value is much higher than observed in our study,
where up to 18% of patients proved positive for BMP7-aAB after
rhBMP7 exposure. The reasons for this discrepancy are unclear, but
might lie in the different treatment regimenapplied, the different assays
used or the criteria applied for deﬁning positivity.
Both studies highlight that natural BMP7-aAB exist and that BMP7-
aAB can be induced by rhBMP7 treatment. This autoimmune response
to the applied rhBMP7 does not develop in all of the treated patients,
but in a subset. The parameters predisposing some patients to BMP7-
aAB are probably similar to those determining the risk of autoimmunity
in the general population, including genetic predisposition [27], obesity
[28], smoking status [29], and other environmental factors. Speciﬁcally,
B-cells are primed to be activated upon a sudden increase in antigen
along with inﬂammatory signals (cytokines) whereas constant antigen
signals in absence of inﬂammation may rather be tolerated [30,31]. The
application of rhBMP7 in fracture patients provides an unprecedented
antigen surge into an inﬂamed environment. Patients that contain
autoreactive B-cells which are in immunological tolerant formmay be-
come activated especially in the context of an ongoing inﬂammation.
These aspects as well as the genetic predisposition to develop autoim-
munity vary between individuals and may account for the heteroge-
neous picture observed. Further studies along this line are needed.
Comparing the aAB against BMP2, the former study reported a prev-
alence of 2.3% in subjects below 65 years of age, and 5.3% in subjects
who are older [26]. Again, these data are well in agreement with our re-
sults in patients and controls. Notably, the prevalence of BMP2-aAB pos-
itive patients was higher in samples collected after rhBMP7 treatment,
however the titers of these aAB were relatively low and close to the
cut-off level. These data imply a high speciﬁcity of therapy-induced
aAB to the actual biological agent usedwith little cross-reactivity to a re-
lated growth factor.
When reconsidering the three main concerns regarding anti-drug
antibodies of biologicals, i.e., (1) neutralization of the drug, (2) immune
reaction by the drug-aAB complexes, and (3) cross-reactivity of the aAB
to the endogenous protein, the ﬁrst issue seems to apply to therapy-
induced BMP7-aAB as they neutralized the activity of the recombinant
protein in vitro and prevented it from activating its signaling cascade.
However, whether the neutralizing effect has any strong and relevant
clinical consequences could not fully be evaluated in this study, due to
the heterogeneity and limited number of aAB-positive subjects. Analyz-
ing consolidation as the most relevant end-point of the treatments, our
data indicate that indeed there was a higher number of BMP7-aAB pos-
itive patients who failed to reach successful fracture gap closure, how-
ever the subjects with the highest BMP7-aAB titers were found in the
group of successfully treated patients. These results are puzzling and
do not allow a clear-cut statement on the clinical importance of the
natural or therapy-induced BMP7-aAB, yet. Cross-reactivity of the
BMP7-aAB to the endogenous protein is likely to occur because the
drug is a recombinant human protein variant with highest similarity
to the endogenous form. However, the short transient nature of the in-
duced BMP7-aAB peaks argues against adverse long term consequences,
except for situations in which the antigen is again provided, e.g. upon
repeated therapy with the biological in case that fracture healing failed.Antibody formation against biologicals has long been known, e.g.
during the course of interferon-β (IFN-β) [32–34], erythropoietin
(EPO) [35] or thrombopoietin (THPO) treatment [36]. In all of these
applications, it was shown that aAB are capable of interfering with the
efﬁcacy of the drug. EPO antibodies were associated with the severe
consequence of pure red cell aplasia [35]. Antibody development
against THPO was associated with thrombocytopenia due to cross-
reaction with the endogenous THPO. The incidence of thrombocytope-
nia was higher in healthy volunteers than in immune compromised
cancer patients, and similar to our study, also the antibodies against
THPO disappeared over time [36]. Anti-IFN-β antibodies are extensively
studied to better characterize their occurrence and effects [26,37,38].
However, the mechanisms underlying the patient-speciﬁc responses
to the biologicals are still far from being understood. All of the treat-
mentsmentioned above are given systemically and over a longer period
of time, in contrast to the rhBMP7, which is applied locally into the frac-
ture gap usually only once. Here, a relatively high amount of rhBMP7 is
suddenly present initiating a fast biological response but its stability and
the actual amount that is actively involved in bone regeneration is difﬁ-
cult to estimate. Similarly, the aAB induced by the treatment are not
characterized by a stable titer and are equally difﬁcult to be assessed
for their potentially interfering capacity and clinical importance.5. Conclusions
Treatment with rhBMP7 triggers bone formation along with a tran-
sient autoimmune response in some patients. The induced BMP7-aAB
are neutralizing in nature, as seen in the in vitro analysis, and may
therefore potentially affect the osteogenic differentiation. This phenom-
enon may be of clinical importance as some patients fail to respond to
the osteoinductive treatment for as yet unknown reasons. However,
the correlation of treatment success (consolidation) with the BMP7-
aAB positivity and BMP7-aAB concentrations failed to provide a clear-
cut picture for a negative role in bone regeneration in our study. Collec-
tively, the transient nature of these therapy-induced BMP7-aAB, the
lack of a general cross-reactivity to BMP2, and the lack of a clear corre-
lation to treatment failure are re-assuring ﬁndings with respect to the
safety of recombinant BMP in fracture healing. It remains to be analyzed
in future studieswhether therapy-induced BMP7-aAB are a problematic
predisposition for a repeated BMP7 treatment in cases of initial treat-
ment failure. We hope that our herein described analytical assays,
which are straightforward, robust and easy to establish, are of help in
further studies addressing this issue.Conﬂicts of interest
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